by John R. Fischer
, Senior Reporter | August 05, 2019
Radiology accessories manufacturer DxTx Medical has acquired the rights to Bayer’s MR endorectal coil product line.
The purchase of the eCoil line of products provides the Pennsylvania-based company with access to high-resolution imaging technologies for examination of prostate, colorectal, cervix, and surrounding pelvis anatomies.
“DxTx Medical is committed to providing medical professionals with technology that enhances their ability to provide the best treatment options for the patients they support,” Xueli Wang, president and CEO of DxTx Medical, told HCB News. “The eCoil MR Endorectal coil is well established in high-resolution imaging, and product support and warranty protection will continue as a mainstay for existing as well as new customers.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The MR Endorectal coil provides a high signal-to-noise ratio (SNR) that equips 1.5T and 3.0T MR scanners with multi-parametric and spectroscopy imaging capabilities. Its influence on the small field of vision and high spatial resolution images improves sensitivity and specificity in diagnosis and helps in treatment planning.
Transfer of the line will take place in a period of phases while DxTx Medical sets up its licensing and distribution infrastructure outside the U.S. The first, which went into effect on August 1, will oversee DxTx Medical manufacturing and distributing products to U.S. providers.
Bayer will continue to support product sales for non-U.S. clientele, marketing under the Medrad eCoil brand, until August 31, at which point DxTx Medical will assume responsibility for product manufacturing and distribution globally — with the exception of Italy, where the transition is expected to take place on September 30.
"The timing to sell the product line fits with our objective to focus investment in growing our core products in CT and MR injectors, contrast agents and informatics," Dennis Durmis, SVP - head of region Americas - radiology at Bayer told HCB News. "Our decision will allow the opportunity for DxTx to innovate and invest in the ecoil segment to benefit our customers and patients."
News of the sale follows the closing of Bayer’s announcement in January to close its Robinson Campus operations in Pittsburgh
in an effort to consolidate the company. Its radiology business at its O’Hara Township, Saxonburg and Indianola, Pittsburgh locations, it said would not be affected by the shutdown. It also previously sold its multi-vendor service operations
in 2017 to Capital Partners and North Park Capital Partners.
DxTx Medical plans to introduce upgraded interface device capabilities to enhance the MR Endorectal coil for new platforms of MR scanners.
Bayer will provide more details on the transition to international customers later this summer.
No financial details of the sale were disclosed.